Myriad Genetics' Lead Drug Candidate Accepting Enrollment for a Phase 3 Clinical Trial
Myriad Genetics' lead drug candidate, FLURIZAN(TM), is currently accepting enrollment for a Phase 3 clinical trial in Alzheimer's disease. This compound is also being studied in a Phase 2b clinical trial for prostate cancer therapy. Myriad has a full pipeline of preclinical drug candidates in development and recently started Phase I human clinical trials for two additional cancer drugs, MPC-6827 and MPC-2130.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.